L’ivermectine et les risques d’hospitalisation dus au COVID-19 : preuves d’une analyse quasi expérimentale basée sur une intervention publique à Mexico.
L’étude scientifique soutient les interventions à base d’ivermectine pour atténuer les effets de la pandémie de COVID-19 sur le système de santé.
| Avec Ivermectine | Sans Ivermectine | |
| Hospitalisés | 0,4% | 1,21% |
Ivermectin and the odds of hospitalization due to COVID-19 : evidence from a quasi-experimental analysis based on a public intervention in Mexico City
https://osf.io/preprints/socarxiv/r93g4/
Submitted : May 04, 2021
Last edited : June 29, 2021Authors : Jose Merino Victor Hugo Borja Oliva Lopez José Alfredo Ochoa Eduardo Clark Lila Petersen Saul Caballero
Version complète en PDF :
http://mai68.org/spip2/IMG/pdf/Coro…
Abstract
Objective
To measure the effect of Mexico City’s population-level intervention –an ivermectin-based Medical Kit – – in hospitalizations during the COVID-19 pandemic.
Methods
A quasi-experimental research design with a Coarsened Exact Matching method using administrative data from hospitals and phone-call monitoring. We estimated logistic-regression models with matched observations adjusting by age, sex, COVID severity, and comorbidities. For robustness checks separated the effect of the kit from phone medical monitoring ; changed the comparison period ; and subsetted the sample by hospitalization occupancy,
Results
We found a significant reduction in hospitalizations among patients who received the ivermectin-based medical kit ; the range of the effect is 52%- 76% depending on model specification.
Conclusions
The study supports ivermectin-based interventions to assuage the effects of the COVID-19 pandemic on the health system.
Paper DOI
10.31235/osf.io/r93g4
https://doi.org/10.31235/osf.io/r93g4
License
CC-By Attribution 4.0 International
Disciplines
Social and Behavioral Sciences
Public Affairs, Public Policy and Public Administration
Health Policy Public Policy
RSS 2.0